This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.

New Research Holds Promise For Restoring Lost Vision

Stanford researchers, funded in part by the National Eye Institute and the Glaucoma Research Foundation, make discovery that may help glaucoma patients who have lost vision.

GRF Scientific Advisors on Collaborative Research

Members of our Scientific Advisory Board talk about the success of the Catalyst for a Cure collaborative research model.

Future Focus: Stem Cell Treatment for Glaucoma

Stem cells are undifferentiated cells which have the potential to develop into many different types of specialized tissues.

Ocular Hypertension Treatment

There are millions of people in the United States who have increased pressure in their eyes (intraocular pressure) without glaucoma. Often this condition is referred to as ocular hypertension.

Catalyst for a Cure: Glaucoma Biomarker to Be Tested

The Catalyst for a Cure (CFC) Biomarker Initiative brings together four research laboratories to find new and sensitive measures for glaucoma.

Restoring Vision: Retinal Nerve Cell Regeneration

Researchers have made great progress in understanding the process of optic nerve degeneration and regeneration in glaucoma.

Glaucoma and the Brain

Researchers now view glaucoma as a disease of the brain — a neurodegenerative disease — rather than simply an eye disease.

Early Retina Cell Changes in Glaucoma Identified

A study published by Andrew D. Huberman, PhD and Rana N. El-Danaf, PhD points to the specific structural features and cell types in the retina that may act as key factors in glaucoma progression.

Can Glaucoma Be Cured?

We hope to one day restore vision lost from glaucoma, but that can’t presently be done.

Dr. Derek S. Welsbie awarded the 2014 Shaffer Prize for Innovative Glaucoma Research

Derek Welsbie, MD, PhD was awarded the 2014 Shaffer Prize for Innovative Glaucoma Research for his study “Evaluating the Role of the c-Jun N-terminal Kinase Cascade in Retinal Ganglion Cell Death.”

Calkins Team Tracking New Options to Treat Glaucoma

“We believe this is an important step toward a new and powerful treatment option for glaucoma patients who are going blind despite efforts to lower or manage their eye pressure.” — David Calkins, PhD

Regenerating Lost Vision in Glaucoma

What can we do when patients have lost functional vision in glaucoma?

Catalyst for a Cure Research Progress 2013

Catalyst for a Cure is a unique approach to research developed by Glaucoma Research Foundation to accelerate the pace of discovery toward a cure for glaucoma.

Interview with Glaucoma Researcher Tonia Rex, PhD

GRF awarded Dr. Tonia Rex the Shaffer Prize for Innovative Glaucoma Research in 2012 for her project investigating a neuroprotective therapy in a model of inherited glaucoma.

Biomarkers for Glaucoma

What is a biomarker? A biomarker is an indicator of a biological condition that, in some cases, can assist in the diagnosis and management of disease.

What Causes Vision Loss in Glaucoma?

Researchers hope that by studying other neurodegenerative diseases, we can identify common causes that will help us develop new treatments for glaucoma.

Eye Drops May Delay or Prevent Glaucoma in African Americans

Eye drops that reduce elevated pressure inside the eye can delay or possibly prevent the onset of glaucoma in African Americans at higher risk for developing the disease, researchers have found.

Catalyst for a Cure Roundtable (CFC1)

These videos with the Catalyst for a Cure researchers were filmed during a roundtable interview discussion in January 2011 at the Palace Hotel in San Francisco.

Catalyst for a Cure (CFC1) Report: Nine Years of Innovation

The Catalyst For a Cure has reshaped the direction of glaucoma research by taking a pioneering approach that should become a model for research in other diseases.

Catalyst for a Cure 2011 Progress Report

The research team identified a period of vulnerability for retinal ganglion cells early in the disease, when these cells are more sensitive to metabolic insults and stressors.

Catalyst for a Cure Identifies Key Early Events in Glaucoma

During the year 2009, the investigators of the Catalyst for a Cure (CFC1) consortium worked together to probe how retinal ganglion cells are damaged and decline in glaucoma.

Brain Holds Early Signs of Glaucoma

In a recent study, David Calkins, PhD discovered that the first sign of injury in glaucoma actually occurs in the brain.

CFC Scientists Reply to Questions about Genetics and Glaucoma

The Catalyst For a Cure (CFC1) researchers are: David Calkins, PhD, Philip Horner, PhD, Nicholas Marsh-Armstrong, PhD, and Monica Vetter, PhD.

Study Proves Lowering IOP Preserves Vision

Before this study was done, there was a difference of opinion on whether intraocular pressure (IOP) was involved in optic nerve damage even when IOP was in the normal range.